M28 Capital Management LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), M28 Capital Management LP reported 11 stock positions worth $77.1 million. Its top holding was Wave Life Sciences (WVE) at 39.9% of the portfolio, followed by Invivyd (IVVD, 13.2%) and Rocket Pharmaceuticals (RCKT, 10.8%). Compared with Q1 2024, it reduced 2. The biggest sale was Silence Therapeutics PLC-ADR (SLN, shares −38%).
- Most Recent 13F
- Q2 2026
- Location
- STAMFORD, CT
- CIK
- 0001807489
- Portfolio Value
- $77.1M (Q2 2024)
- SEC Filing
- 0000902664-24-005090 ↗ filed Aug 13, 2024
Holdings Value
Holdings 11 stocks · $77.1M
| WVE Wave Life Sciences Ltd. | 39.88% | 6,164,548 | $30.8M | Reduce -11.9% |
| IVVD Invivyd Inc. | 13.19% | 9,248,250 | $10.2M | No change |
| RCKT Rocket Pharmaceuticals Inc. | 10.76% | 385,680 | $8.3M | No change |
| GUTS Fractyl Health Inc. | 10.27% | 1,856,117 | $7.9M | No change |
| SWTX Springworks Therapeutics Inc. | 5.39% | 110,400 | $4.2M | No change |
| SLN Silence Therapeutics PLC-ADR | 4.56% | 185,100 | $3.5M | Reduce -38.2% |
| BBIO Bridgebio Pharma Inc. | 3.98% | 121,200 | $3.1M | No change |
| CRIS Curis Inc. | 3.77% | 421,951 | $2.9M | No change |
| TGTX TG Therapeutics Inc. | 3.73% | 161,600 | $2.9M | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 2.27% | 67,400 | $1.8M | No change |
| PRQR Proqr Therapeutics NV | 2.19% | 1,019,498 | $1.7M | No change |
Portfolio Sells Q1 2024 → Q2 2024
Portfolio Buys Q1 2024 → Q2 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $47.2M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q1 2026 | 9 | $53.8M | WVE, IVVD, TGTX, ARWR, PRQR |
| Q4 2025 | 9 | $137.6M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q3 2025 | 9 | $68.0M | WVE, IVVD, TGTX, GUTS, ARWR |
| Q2 2025 | 9 | $58.6M | WVE, IVVD, TGTX, GUTS, PRQR |
| Q1 2025 | 11 | $73.0M | WVE, TGTX, IVVD, BBIO, RCKT |
| Q4 2024 | 11 | $101.9M | WVE, TGTX, RCKT, IVVD, SWTX |
| Q3 2024 | 11 | $91.0M | WVE, IVVD, RCKT, GUTS, TGTX |
| Q2 2024 | 11 | $77.1M | WVE, IVVD, RCKT, GUTS, SWTX |
| Q1 2024 | 11 | $135.3M | WVE, IVVD, GUTS, RCKT, SLN |